title: Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
authors: Cardiovascular Centre, University Hospital Zurich, Zurich, Switzerland.
authors: S
authors: S
authors: Reidt
authors: M
authors: M
authors: Namdar
authors: A
authors: A
authors: Serra
authors: P A
authors: PA
authors: Krayenbühl
authors: C
authors: C
authors: Gruner
authors: D I
authors: DI
authors: Keller
authors: T F
authors: TF
authors: Lüscher
authors: C
authors: C
authors: Schmied
mesh_terms: D018450:Disease Progression; D016903:Drug Monitoring / Q000379:methods; D057915:Drug Substitution / Q000379:methods*; D004452:Echocardiography; D056947:Enzyme Replacement Therapy / Q000379:methods; D000795:Fabry Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005919:Glomerular Filtration Rate; D006801:Humans; D007527:Isoenzymes / Q000008:administration & dosage*; D008297:Male; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000008:administration & dosage*
chemical_list: D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta